Navigation Links
Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
Date:3/23/2010

MALVERN, Pa., March 23 /PRNewswire/ -- Garnet BioTherapeutics, Inc. ("Garnet"), a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York.  GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.  The trial will assess the safety and efficacy of GBT009 for the treatment of incisional wounds following breast reconstruction surgery.

"Recent advances in reconstructive surgery mean that women who have breast cancer today have greater choices that were not widely available 10 years ago," according to Joseph M. Serletti, MD, Chief of the Division of Plastic Surgery at the University of Pennsylvania School of Medicine, who specializes in breast reconstruction in cancer patients.  "There are definite advantages to this surgery which uses the patient's own tissue to create a natural breast reconstruction.  However, the limitation of this surgery is scarring in the area of the body where the tissue was taken.  We are excited about the potential of this novel cell therapy which meets an unmet need for patients and surgeons looking for more options to improve scar formation and repair damaged tissue," he added.  Dr. Serletti is a Principal Investigator for the study and serves as a consultant to Garnet BioTherapeutics, Inc.'/>"/>

SOURCE Garnet BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
2. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
3. Oxygen Biotherapeutics, Inc. Expands Board of Directors
4. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
5. Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing
6. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
7. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
8. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
11. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... second quarter financial results on Tuesday, July 29, 2014, after ... be followed by a conference call with the investment community ... will be Robert A. Bradway , chairman and chief ... Live audio of the conference call will be ...
(Date:7/24/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI) ("DelMar" "the company") announced today that the company,s ... year from December 31 to June 30. Accordingly, DelMar will ... 2014. Jeffrey Bacha , president and CEO ... an important step in achieving our goal of obtaining a ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... shows,significant 35% reduction in subsequent osteoporotic fractures with Reclast -- ... 28% reduction in overall mortality seen in study patients ... treated with Reclast, -- ... fracture despite high risk of morbidity and mortality (1) -- ...
... (Nasdaq: TGEN ) today reported on the ... (NIH) Recombinant DNA Advisory,Committee (RAC), which reviewed the ... death of a patient participating in the,Company,s Phase ... The clinical case was presented for the first ...
Cached Medicine Technology:First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 2First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 3First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 4First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 6First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 7First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 8Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 2Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 3Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 4
(Date:7/24/2014)... (PRWEB) July 24, 2014 In ... Tuesday, President Obama cited the Atlanta BeltLine Workforce ... programs from across the country ( http://www.whitehouse.gov/ready-to-work ... an essential pillar of U.S. economic strategy and ... , “This recognition from President Obama highlights the ...
(Date:7/24/2014)... University, working with high-throughput data generated by breast ... devised a computational method to determine how gene ... malignant and as they respond to potential cancer ... interact with each other in laboratory-grown cells is ... online journal PLOS Computational Biology . , ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Lynn E. Taylor, M.D., director of The ... the July, 2014 Rhode Island Medical Journal ... eliminating hepatitis c virus infection (hep c or ... capacity to address other health challenges, and improve ... the United States, Taylor says, include lack of ...
(Date:7/24/2014)... July 24, 2014 Plaintiffs in ... ) against the manufacturer of Delatestryl, alleging they ... with the low testosterone injection, Bernstein Liebhard LLP ... in the Ontario Superior Court of Justice on ... low testosterone therapy is associated with an increased ...
Breaking Medicine News(10 mins):Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3
... System in U.S. receives a low score (66 out ... first national scoring system of the 18-member Commonwealth Fund ... in promoting better health care systems for low-income and ... rankings were based on the scoring in various areas ...
... recent study reports that while teachers and students prefer ... and abortion rates especially in UK schools. When teen ... many influencing factors – the officials said. The study, ... was published in the British Medical Journal, covered about ...
... Fr Angelo D'Agostino SJ, a Jesuit priest, well-known for his ... Monday at the age of 80. ,He was the ... centre for abandoned HIV-positive children. ,Fr Joachim Omolo Ouko ... tribute to Fr Angelo D'Agostino SJ ,He said, "Father D'Agostino ...
... Ovarian cancer continues to be a stealthy killer in Australia ... in the advanced stages. Reports reveal that less than half ... beyond five years. Only about 42% of patients survive when ... a Federal government report. The survival rate is low for ...
... in how insects develop from larvae to adults have ... failure// to be effective in preventing and reducing cardiac ... Davis research published in the early online edition of ... ,The research, led by cardiologist and cell biologist Nipavan ...
... woman and a mother of two children died of breast cancer ... in Sheffield. //Dr.John Philip was not qualified to read mammograms according ... Trust, David Jackson. ,The woman who is identified as ... Philip told her that she was normal. When she went for ...
Cached Medicine News:Health News:Insect Protein Effective for Treating Heart Enlargement, Arrythmias 2
... TraceMasterVue is a cutting-edge ... rich, thin-client functionality and convenient, ... clinical, administrative and information technology ... productivity, lower costs, and improved ...
... testing within reach of virtually any facility...from ... most advanced cardiology hospital. This PC-based system ... options for a Philips ergonomic stress cart ... StressVue is designed to interface with the ...
A component of the 3M Littmann Electronic Stethoscope Model 4000...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
Medicine Products: